MARKET

ITCI

ITCI

INTRA CELLULAR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

42.86
-0.45
-1.04%
Opening 13:51 06/16 EDT
OPEN
42.84
PREV CLOSE
43.31
HIGH
43.41
LOW
42.44
VOLUME
139.34K
TURNOVER
--
52 WEEK HIGH
43.82
52 WEEK LOW
17.26
MARKET CAP
3.48B
P/E (TTM)
-13.5650
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15)
Benzinga · 5h ago
Here's Why We Think Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Compensation Looks Fair for the time being
Performance at Intra-Cellular Therapies, Inc. ( NASDAQ:ITCI ) has been reasonably good and CEO Sharon Mates has done a...
Simply Wall St. · 1d ago
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10)
Benzinga · 5d ago
The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9)
Benzinga · 6d ago
Stocks That Hit 52-Week Highs On Wednesday
    During Wednesday's morning trading, 251 companies set new 52-week highs.
Benzinga · 06/09 14:05
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7)
Benzinga · 06/08 13:17
Looking Into Intra-Cellular Therapies's Return On Capital Employed
During Q1, Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $15.88 million. However, earnings decreased 13.23%, resulting in a loss of $53.22 million. In Q4, Intra-Cellular Therapies brought in $12.45 million in sales but lost $61.33 millio...
Benzinga · 06/07 14:02
CAPLYTA(R) (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology
Pooled analysis of 3 randomized, double-blind, pacebo-cotrolled trials supports the safety and the distinct and favorable tolerability profile of lumateperone 42 mg
GlobeNewswire · 06/07 12:11
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ITCI. Analyze the recent business situations of INTRA CELLULAR through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ITCI stock price target is 52.13 with a high estimate of 81.00 and a low estimate of 40.00.
EPS
Institutional Holdings
Institutions: 240
Institutional Holdings: 72.73M
% Owned: 89.57%
Shares Outstanding: 81.20M
TypeInstitutionsShares
Increased
50
2.54M
New
23
3.53M
Decreased
63
3.55M
Sold Out
30
1.39M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.58%
Pharmaceuticals & Medical Research
-0.04%
Key Executives
Chief Financial Officer/Senior Vice President - Finance/Treasurer/Assistant Secretary
Lawrence Hineline
Executive Vice President/General Counsel/Secretary
Michael Halstead
Executive Vice President
Mark Neumann
Senior Vice President
Suresh Durgam
Lead Director/Independent Director
Robert Van Nostrand
Director/Chief Executive Officer/President/Chairman
Sharon Mates
Independent Director
Christopher Alafi
Independent Director
Richard Lerner
Independent Director
Joel Marcus
Independent Director
Rory Riggs
No Data
About ITCI
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).

Webull offers kinds of Intra-Cellular Therapies Inc stock information, including NASDAQ:ITCI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ITCI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ITCI stock methods without spending real money on the virtual paper trading platform.